4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9 Ịdị ọcha>98.5% (HPLC) Ụlọ ọrụ etiti Lenvatinib Mesylate
Ruifu Chemical Supply Lenvatinib Mesylate Intermediates nwere ịdị ọcha dị elu
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1- (2-Chloro-4-Hydroxyphenyl) -3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5- (Methoxymethylene) -2,2-Dimethyl-1,3-Dioxane-4,6-Dion CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Aha Chemical | 4-Chloro-7-Methoxyquinoline-6-Carboxamide |
Ụdị okwu | 4-Chloro-7-Methoxy-6-Quinolinecarboxamide;Lenvatinib adịghị ọcha 12;Lenvatinib adịghị ọcha B;Lenvatinib adịghị ọcha LFS-B |
Nọmba CAS | 417721-36-9 |
Nọmba CAT | RF-PI1971 |
Ọnọdụ Ahịa | N'ahịa, Ikike Mmepụta 50MT/Afọ |
Usoro ihe omimi | C11H9ClN2O2 |
Ibu molekụla | 236.65 |
Ebe Na-agbaze | > 205 ℃ (Dec.) |
Njupụta | 1.380±0.060 g/cm3 |
Ụdị | Ruifu Chemical |
Ihe | Nkọwapụta |
Ọdịdị | Gbanyụọ-Ọcha ka ntụ ntụ edo edo dị ọkụ |
Ụzọ ịdị ọcha / nyocha | > 98.5% (HPLC) |
Ọnwụ na ihicha | <0.50% |
Ihe fọdụrụ na mgbanye | <0.50% |
Mgbakọta adịghị ọcha | <1.50% |
Ọnụ ego nke Proton NMR Spectrum | Dabara na Ọdịdị |
Nlele ọkọlọtọ | Standardkpụrụ ụlọ ọrụ |
Ojiji | Ndị etiti Lenvatinib Mesylate (CAS: 857890-39-2) |
ngwugwu: Kalama, Aluminom foil bag, 25kg / Cardboard Drum, ma ọ bụ dị ka ndị ahịa chọrọ
Ọnọdụ Nchekwa:Na-echekwa n'ime akpa ndị a kpuchiri ekpuchi na ebe dị jụụ na nke kpọrọ nkụ;Chebe site na ìhè na mmiri mmiri
4-Chloro-7-Methoxyquinoline-6-Carboxamide (CAS: 417721-36-9) ka a na-ejikarị dị ka etiti nke Lenvatinib Mesylate (CAS: 857890-39-2).Mepụtara Eisai Inc., lenvatinib mesylate bụ vaskụla endothelial growth factor receptor (VEGF) inhibitor nke nwere ọrụ megide VEGF subtypes 1, 2, na 3 ma kwadoro ya na FDA na 2015 maka ọgwụgwọ ọrịa cancer thyroid dị iche iche nke bụ na mpaghara. na-emegharị ugboro ugboro, metastatic, ma ọ bụ na-aga n'ihu ma ọ naghị anabata ọgwụgwọ iodine redioaktivu.Na Mee 2016, FDA kwadoro ọgwụ ahụ dị ka ọgwụgwọ ngwakọta na everolimus maka ọgwụgwọ nke carcinoma renal renal cell.N'ihi na VEGF (na fibroblast growth factor receptors, nke a maara dị ka FGFRs) na-eche na ha na-ekere òkè na ụzọ mgbaàmà nke obi, VEGF2R na mgbochi FGFR na-eche na ọ bụ usoro n'azụ isi mmetụta nke lenvatinib mesylate, nke bụ ọbara mgbali elu.